DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Trastuzumab emtansine is an investigational drug.
There have been 76 clinical trials for Trastuzumab emtansine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Stomach Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dana-Farber Cancer Institute.
There are thirty-eight US patents protecting this investigational drug and seven hundred and eighty-two international patents.
Recent Clinical Trials for Trastuzumab emtansine
|Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer||University of Rochester||Phase 2|
|Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer||National Cancer Institute (NCI)||Phase 2|
|Abemaciclib With or Without T-DM1 for the Treatment of HER2-Positive Metastatic Breast Cancer||Academic and Community Cancer Research United||Phase 2|
Top disease conditions for Trastuzumab emtansine
Top clinical trial sponsors for Trastuzumab emtansine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Trastuzumab emtansine||Start Trial||Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds||Array BioPharma Inc. (Boulder, CO)||Start Trial|
|Trastuzumab emtansine||Start Trial||Methods for the treatment of HER2 amplified cancer||Pharmacyclics LLC (Sunnyvale, CA)||Start Trial|
|Trastuzumab emtansine||Start Trial||Encapsulated agents and methods of making and using thereof||University of Georgia Research Foundation, Inc. (Athens, GA)||Start Trial|
|Trastuzumab emtansine||Start Trial||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Trastuzumab emtansine||Argentina||074052||2028-10-22||Start Trial|
|Trastuzumab emtansine||Argentina||112833||2028-10-22||Start Trial|
|Trastuzumab emtansine||Australia||2009308465||2028-10-22||Start Trial|
|Trastuzumab emtansine||Australia||2015200511||2028-10-22||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|